Pharsight

1. List of Abilify Maintena Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10525057	OTSUKA PHARM CO LTD	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function	Mar, 2034 (11 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Maintenance monotherapy treatment of bipolar 1 disorder; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; Treatment of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
300 mg/vial and 400 mg/vial	20 Dec, 2021	1		24 Sep, 2033

Strength	Dosage	Availability
300MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
300MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

2. List of Abraxane drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511046	ABRAXIS BIOSCIENCE	Methods of treating pancreatic cancer	Jan, 2034 (10 years from now)
US9511046 (Pediatric)	ABRAXIS BIOSCIENCE	Methods of treating pancreatic cancer	Jul, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
M	Dec 6, 2022
Pediatric Exclusivity (PED)	Jun 6, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of pancreatic cancer

Dosage: POWDER;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg/vial	11 Dec, 2015	1		27 Oct, 2024

Strength	Dosage	Availability
100MG/VIAL	POWDER;INTRAVENOUS	Prescription

3. List of Adempas drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10662188	BAYER HLTHCARE	Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate	Feb, 2034 (11 years from now)
US11203593	BAYER HLTHCARE	Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate	Feb, 2034 (11 years from now)

Drugs and Companies using RIOCIGUAT ingredient

Market Authorisation Date: 08 October, 2013

Treatment: Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (cteph), (who group 4) after surgical treatment, or inoperable cteph, to improve exercise capacity and who functional class; Treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg	10 Oct, 2017	3	01 Sep, 2022	04 Dec, 2026	Deferred

Strength	Dosage	Availability
0.5MG	TABLET;ORAL	Prescription
1MG	TABLET;ORAL	Prescription
1.5MG	TABLET;ORAL	Prescription
2MG	TABLET;ORAL	Prescription
2.5MG	TABLET;ORAL	Prescription

4. List of Airduo Digihaler drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066957	TEVA PHARM	Dry powder inhaler	Oct, 2034 (11 years from now)
US9415008	TEVA PHARM	Dry powder inhaler	Oct, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
M	Jul 9, 2024
Pediatric Exclusivity (PED)	Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: Treatment of asthma

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription

5. List of Alkindi Sprinkle drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649280	ETON	Composition comprising hydrocortisone	May, 2034 (11 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Market Authorisation Date: 29 September, 2020

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

Strength	Dosage	Availability
0.5MG	GRANULE;ORAL	Prescription
1MG	GRANULE;ORAL	Prescription
2MG	GRANULE;ORAL	Prescription
5MG	GRANULE;ORAL	Prescription

6. List of Alunbrig drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9611283	TAKEDA PHARMS USA	Methods for inhibiting cell proliferation in ALK-driven cancers	Apr, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 28, 2022
Orphan Drug Exclusivity (ODE)	May 22, 2027
New Indication (I)	May 22, 2023

Drugs and Companies using BRIGATINIB ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

Strength	Dosage	Availability
30MG	TABLET;ORAL	Prescription
90MG	TABLET;ORAL	Prescription
180MG	TABLET;ORAL	Prescription

7. List of Arikayce Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566234	INSMED INC	Systems for treating pulmonary infections	Jan, 2034 (10 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 28, 2025
Generating Antibiotic Incentives Now (GAIN)	Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

Strength	Dosage	Availability
EQ 590MG BASE/8.4ML	SUSPENSION, LIPOSOMAL;INHALATION	Prescription

8. List of Aubagio drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186346	SANOFI AVENTIS US	Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients	Feb, 2034 (11 years from now)
US9186346 (Pediatric)	SANOFI AVENTIS US	Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients	Aug, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
M	Apr 30, 2024
Pediatric Exclusivity (PED)	Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

Market Authorisation Date: 12 September, 2012

Treatment: Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
7 mg and 14 mg	12 Sep, 2016	21	27 Jul, 2018	04 Feb, 2034	Eligible

Strength	Dosage	Availability
7MG	TABLET;ORAL	Prescription
14MG	TABLET;ORAL	Prescription

9. List of Austedo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550780 (Pediatric)	TEVA BRANDED PHARM	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar, 2034 (11 years from now)
US9233959 (Pediatric)	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar, 2034 (11 years from now)
US9296739 (Pediatric)	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar, 2034 (11 years from now)
US9814708 (Pediatric)	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Apr 3, 2024
New Chemical Entity Exclusivity (NCE)	Apr 3, 2022
M	Jun 24, 2024
Pediatric Exclusivity (PED)	Oct 3, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: October, 2023

Market Authorisation Date: 03 April, 2017

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
6 mg, 9 mg and 12 mg	05 Apr, 2021	2		07 Mar, 2036

Strength	Dosage	Availability
6MG	TABLET;ORAL	Prescription
9MG	TABLET;ORAL	Prescription
12MG	TABLET;ORAL	Prescription

10. List of Auvelity drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11517542	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11524007	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10463634	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US11517543	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11141388	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11213521	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11129826	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11123343	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10966974	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10512643	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US10105361	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US11524008	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11497721	AXSOME	NA	Nov, 2034 (11 years from now)
US11478468	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11510918	AXSOME	NA	Nov, 2034 (11 years from now)
US9968568	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US10092560	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US11311534	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10105327	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US11382874	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11364233	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US9457025	AXSOME	Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan	Nov, 2034 (11 years from now)
US10058518	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US9278095	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US9867819	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US9168234	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US9861595	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US9700553	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US11357744	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11344544	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US9486450	AXSOME	Hydroxybupropion and related compounds as modulators of drug plasma levels	Nov, 2034 (11 years from now)
US9474731	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US9375429	AXSOME	Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan	Nov, 2034 (11 years from now)
US9421176	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US9408815	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US9763932	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US9205083	AXSOME	Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan	Nov, 2034 (11 years from now)
US9707191	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US10898453	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11433067	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US9700528	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US9370513	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US9457023	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US9238032	AXSOME	Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan	Nov, 2034 (11 years from now)
US11096937	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11298352	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10966941	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11298351	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11090300	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10894047	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10064857	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11291665	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11291638	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10786469	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US11253492	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10881657	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10874663	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10799497	AXSOME	Combination of dextromethorphan and bupropion for treating depression	Nov, 2034 (11 years from now)
US11058648	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11273133	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10864209	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10806710	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10881624	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US10786496	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US11020389	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11185515	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10945973	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11285146	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11285118	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10596167	AXSOME	Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan	Nov, 2034 (11 years from now)
US11439636	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US9314462	AXSOME	Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US9198905	AXSOME	Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US11426401	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11426370	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11419867	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10772850	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11273134	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11253491	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11234946	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10548857	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US11229640	AXSOME	Combination of dextromethorphan and bupropion for treating depression	Nov, 2034 (11 years from now)
US10874665	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10933034	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10251879	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10092561	AXSOME	Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan	Nov, 2034 (11 years from now)
US10894046	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11191739	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10874664	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10080727	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)
US11197839	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11147808	AXSOME	Method of decreasing the fluctuation index of dextromethorphan	Nov, 2034 (11 years from now)
US11207281	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US11141416	AXSOME	Bupropion as a modulator of drug activity	Nov, 2034 (11 years from now)
US10780066	AXSOME	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects	Nov, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Aug 18, 2025

Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient

Market Authorisation Date: 18 August, 2022

Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
105MG;45MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

11. List of Ayvakit drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9944651	BLUEPRINT MEDICINES	Compositions useful for treating disorders related to kit	Oct, 2034 (11 years from now)
US9200002	BLUEPRINT MEDICINES	Compositions useful for treating disorders related to KIT	Oct, 2034 (11 years from now)
US9994575	BLUEPRINT MEDICINES	Compositions useful for treating disorders related to kit	Oct, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 9, 2025
New Indication (I)	Jun 16, 2024
Orphan Drug Exclusivity (ODE)	Jan 9, 2027

Drugs and Companies using AVAPRITINIB ingredient

NCE-1 date: January, 2024

Market Authorisation Date: 09 January, 2020

Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; Treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leukemia (mcl)

Dosage: TABLET;ORAL

Strength	Dosage	Availability
25MG	TABLET;ORAL	Prescription
50MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription
200MG	TABLET;ORAL	Prescription
300MG	TABLET;ORAL	Prescription

12. List of Barhemsys drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9084765	ACACIA	Use of amisulpride as an anti-emetic	Feb, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Prevention of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
5MG/2ML (2.5MG/ML)	SOLUTION;INTRAVENOUS	Prescription
10MG/4ML (2.5MG/ML)	SOLUTION;INTRAVENOUS	Prescription

13. List of Bosulif drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103497	PF PRISM CV	Treatment of imatinib resistant leukemia	Feb, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 19, 2024

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Market Authorisation Date: 04 September, 2012

Treatment: A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at 949t>c; A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at f317l

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg and 500 mg	06 Sep, 2016	2		23 Nov, 2026
400 mg	25 Oct, 2018	1		23 Nov, 2026

Strength	Dosage	Availability
EQ 100MG BASE	TABLET;ORAL	Prescription
EQ 400MG BASE	TABLET;ORAL	Prescription
EQ 500MG BASE	TABLET;ORAL	Prescription

14. List of Brukinsa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9447106	BEIGENE	Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators	Apr, 2034 (11 years from now)
US11142528	BEIGENE	Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators	Apr, 2034 (11 years from now)
US10570139	BEIGENE	Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators	Apr, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 14, 2024
Orphan Drug Exclusivity (ODE)	Sep 14, 2028
New Indication (I)	Sep 14, 2024

Drugs and Companies using ZANUBRUTINIB ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 14 November, 2019

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; For the treatment of patients with waldenstrom's macroglobulinemia; Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
80MG	CAPSULE;ORAL	Prescription

15. List of Camzyos drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9181200	BRISTOL	Pyrimidinedione compounds	Jun, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585883	BRISTOL	Pyrimidinedione compounds	Jun, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 28, 2027

Drugs and Companies using MAVACAMTEN ingredient

NCE-1 date: April, 2026

Market Authorisation Date: 28 April, 2022

Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
2.5MG	CAPSULE;ORAL	Prescription
5MG	CAPSULE;ORAL	Prescription
10MG	CAPSULE;ORAL	Prescription
15MG	CAPSULE;ORAL	Prescription

16. List of Caplyta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11026951	INTRA-CELLULAR	Methods of treating bipolar disorder	Dec, 2034 (11 years from now)
US10960009	INTRA-CELLULAR	Methods of treating schizophrenia and depression	Dec, 2034 (11 years from now)
US9956227	INTRA-CELLULAR	Method for the treatment of residual symptoms of schizophrenia	Dec, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 20, 2024
New Indication (I)	Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: December, 2023

Market Authorisation Date: 20 December, 2019

Treatment: Treatment of bipolar i disorder, bipolar ii disorder, or bipolar depression; Treatment of schizophrenia; Treatment of schizophrenia with improvement in residual symptoms of schizophrenia

Dosage: CAPSULE;ORAL

17. List of Cibinqo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9035074	PFIZER	Pyrrolo[2,3-D]pyrimidine derivatives	Feb, 2034 (11 years from now)
US9545405	PFIZER	Pyrrolo[2,3-D]pyrimidine derivatives	Feb, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929	PFIZER	Pyrrolo[2,3-D]pyrimidine derivatives	Feb, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 14, 2027

Drugs and Companies using ABROCITINIB ingredient

NCE-1 date: January, 2026

Market Authorisation Date: 14 January, 2022

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET;ORAL

18. List of Clenpiq drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624879	FERRING PHARMS INC	Liquid pharmaceutical composition	Jun, 2034 (11 years from now)
US11191753	FERRING PHARMS INC	Liquid pharmaceutical composition	Jun, 2034 (11 years from now)
US9827231	FERRING PHARMS INC	Liquid pharmaceutical composition	Jun, 2034 (11 years from now)

Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient

Market Authorisation Date: 28 November, 2017

Treatment: For cleansing of the colon as a preparation for colonoscopy; For cleansing the large intestine as a preparation for colonoscopy

Dosage: SOLUTION;ORAL

19. List of Contrave drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10828294	NALPROPION	Compositions and methods for weight loss in at risk patient populations	Jul, 2034 (11 years from now)
US10231964	NALPROPION	Compositions and methods for weight loss in at risk patient populations	Jul, 2034 (11 years from now)
US10835527	NALPROPION	Compositions and methods for reducing major adverse cardiovascular events	Jul, 2034 (11 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

20. List of Cosela drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9487530	G1 THERAP	Transient protection of normal cells during chemotherapy	Mar, 2034 (11 years from now)
US10085992	G1 THERAP	Transient protection of normal cells during chemotherapy	Mar, 2034 (11 years from now)
US10966984	G1 THERAP	Transient protection of normal cells during chemotherapy	Mar, 2034 (11 years from now)
US11040042	G1 THERAP	Transient protection of normal cells during chemotherapy	Mar, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: February, 2025

Market Authorisation Date: 12 February, 2021

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer

Dosage: POWDER;INTRAVENOUS

21. List of Cotellic drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11087354	GENENTECH INC	Combination therapies	Jun, 2034 (11 years from now)
US11087354 (Pediatric)	GENENTECH INC	Combination therapies	Dec, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 10, 2022
New Indication (I)	Oct 28, 2025
M	Jul 28, 2025
Pediatric Exclusivity (PED)	Jan 28, 2026

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Market Authorisation Date: 10 November, 2015

Treatment: Method of using cobimetinib for the treatment of melanoma

Dosage: TABLET;ORAL

22. List of Dexycu Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028965	EYEPOINT PHARMS	Use of sustained release dexamethasone in post-cataract surgery inflammation	May, 2034 (11 years from now)
US10159683	EYEPOINT PHARMS	Use of sustained release dexamethasone in post-cataract surgery inflammation	May, 2034 (11 years from now)
US10022502	EYEPOINT PHARMS	Dose guides for injection syringe	Jun, 2034 (11 years from now)

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 09 February, 2018

Treatment: Treatment of postoperative inflammation

Dosage: SUSPENSION;INTRAOCULAR

23. List of Dificid drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808530	CUBIST PHARMS LLC	Composition of tiacumicin compounds	May, 2034 (11 years from now)
US9808530 (Pediatric)	CUBIST PHARMS LLC	Composition of tiacumicin compounds	Nov, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Jan 24, 2023
Orphan Drug Exclusivity (ODE)	Jan 24, 2027
Pediatric Exclusivity (PED)	Jul 24, 2023

Drugs and Companies using FIDAXOMICIN ingredient

Market Authorisation Date: 24 January, 2020

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

24. List of Dilaudid drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248229	FRESENIUS KABI USA	Packaging system for oxygen-sensitive drugs	Mar, 2034 (11 years from now)

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 11 January, 1984

Treatment: NA

Dosage: INJECTABLE;INJECTION

25. List of Doryx drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511031	MAYNE PHARMA	Controlled release doxycycline	Oct, 2034 (11 years from now)
US9295652	MAYNE PHARMA	Controlled release doxycycline	Oct, 2034 (11 years from now)
US9446057	MAYNE PHARMA	Controlled release doxycycline	Dec, 2034 (11 years from now)

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Market Authorisation Date: 06 May, 2005

Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

26. List of Durysta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9980974	ALLERGAN INC	Prostamide-containing intraocular implants and methods of use thereof	Oct, 2034 (11 years from now)
US9492316	ALLERGAN INC	Prostamide-containing intraocular implants and methods of use thereof	Oct, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Mar 4, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

27. List of Epclusa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086011	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jan, 2034 (11 years from now)
US11116783	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jan, 2034 (11 years from now)
US9757406	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jan, 2034 (11 years from now)
US9757406 (Pediatric)	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jul, 2034 (11 years from now)
US11116783 (Pediatric)	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jul, 2034 (11 years from now)
US10086011 (Pediatric)	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jul, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jun 10, 2028
New Strength (NS)	Mar 19, 2023
M	Apr 27, 2025
New Dosing Schedule (D)	Nov 15, 2022
New Patient Population (NPP)	Mar 19, 2023
Pediatric Exclusivity (PED)	May 15, 2023

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 28 June, 2016

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL

28. List of Epinephrine drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039728	BELCHER	More potent and less toxic formulations of epinephrine and methods of medical use	Aug, 2034 (11 years from now)
US10004700	BELCHER	More potent and less toxic formulations of epinephrine and methods of medical use	Aug, 2034 (11 years from now)
US9283197	BELCHER	More potent and less toxic formulations of epinephrine and methods of medical use	Aug, 2034 (11 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 29 July, 2014

Treatment: Increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock; Emergency treatment of allergic reactions (type 1), including anaphylaxis; A method of treating allergic reaction, anaphylaxis, anaphylactic shock, or combination thereof by an injection of at least one dosage of the injectable liquid pharmaceutical; Emergency treatment of allergic reactions (type i), including anaphylaxis; Induction and maintenance of mydriasis during intraocular surgery

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS; SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

29. List of Evomela drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10040872	ACROTECH	Alkylated cyclodextrin compositions and processes for preparing and using the same	Jan, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Mar 10, 2023

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

30. List of Evzio drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517307	KALEO INC	Devices and methods for delivering opioid antagonists including formulations for naloxone	Jul, 2034 (11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: Use of an auto injector to administer naloxone hcl

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

31. List of Evzio (autoinjector) drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517307	KALEO INC	Devices and methods for delivering opioid antagonists including formulations for naloxone	Jul, 2034 (11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: Use of an auto injector to administer naloxone hcl

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

32. List of Exondys 51 drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9506058	SAREPTA THERAPS INC	Compositions for treating muscular dystrophy	Mar, 2034 (11 years from now)
US10364431	SAREPTA THERAPS INC	Compositions for treating muscular dystrophy	Mar, 2034 (11 years from now)
US10337003	SAREPTA THERAPS INC	Compositions for treating muscular dystrophy	Mar, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 19, 2023

Drugs and Companies using ETEPLIRSEN ingredient

Market Authorisation Date: 19 September, 2016

Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping

Dosage: SOLUTION;INTRAVENOUS

33. List of Firdapse drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10793893	CATALYST PHARMS	Methods of administering 3,4-diaminopyridine	May, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 28, 2023
Orphan Drug Exclusivity (ODE)	Nov 28, 2025
New Patient Population (NPP)	Sep 29, 2025

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

34. List of Fulvestrant drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833459	FRESENIUS KABI USA	Fulvestrant formulations	Feb, 2034 (11 years from now)
US10188663	FRESENIUS KABI USA	Fulvestrant formulations	Feb, 2034 (11 years from now)
US9271990	FRESENIUS KABI USA	Fulvestrant formulations	May, 2034 (11 years from now)

Drugs and Companies using FULVESTRANT ingredient

Market Authorisation Date: 20 May, 2019

Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women

Dosage: SOLUTION;INTRAMUSCULAR

35. List of Furoscix drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884039	SCPHARMACEUTICALS	Pharmaceutical formulations for subcutaneous administration of furosemide	Apr, 2034 (11 years from now)
US10272064	SCPHARMACEUTICALS	Pharmaceutical formulations for subcutaneous administration of furosemide	Apr, 2034 (11 years from now)
US11433044	SCPHARMACEUTICALS	Pharmaceutical formulations for subcutaneous administration of furosemide	Apr, 2034 (11 years from now)

Drugs and Companies using FUROSEMIDE ingredient

Market Authorisation Date: 07 October, 2022

Treatment: Use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure

Dosage: SOLUTION;SUBCUTANEOUS

36. List of Ganzyk-rtu drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486530	EXELA PHARMA	Ganciclovir compositions and related methods	Sep, 2034 (11 years from now)

Drugs and Companies using GANCICLOVIR ingredient

Market Authorisation Date: 17 February, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

37. List of Giapreza drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11096983	LA JOLLA PHARMA	Angiotensin II alone or in combination for the treatment of hypotension	Dec, 2034 (11 years from now)
US10028995	LA JOLLA PHARMA	Angiotensin II alone or in combination for the treatment of hypotension	Dec, 2034 (11 years from now)
US9220745	LA JOLLA PHARMA	Angiotensin II alone or in combination for the treatment of hypotension	Dec, 2034 (11 years from now)
US10493124	LA JOLLA PHARMA	Angiotensin II alone or in combination for the treatment of hypotension	Dec, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 21 December, 2017

Treatment: Treating distributive shock with angiotensin ii; Treating septic shock with angiotensin ii; Maintaining mean arterial pressure of about 65 mmhg or above with about 1 ng/kg/min to about 40 ng/kg/min angiotensin ii in hypotensive patients treated with vasopressin or a vasopressin analogue and reducing vasopressin or vasopressin analogue use; Maintaining mean arterial pressure of about 65 mmhg or higher with angiotensin ii in shock patients treated with catecholamines and reducing catecholamine use; Treating high output shock with angiotensin ii by increasing mean arterial pressure in patients treated with catecholamines and reducing catecholamine use; Treating low blood pressure with angiotensin ii at an initial rate of about 20 ng/kg/min and titrating down to achieve and/or maintain a map of about 65 mm hg or above

Dosage: SOLUTION;INTRAVENOUS

38. List of Givlaari drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11028392	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of the ALAS1 gene	Oct, 2034 (11 years from now)
US10119143	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of the ALAS1 gene	Oct, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 20, 2024
Orphan Drug Exclusivity (ODE)	Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

39. List of Glyxambi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US9949998	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Jun, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
M	Jul 3, 2022

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Market Authorisation Date: 30 January, 2015

Dosage: TABLET;ORAL

40. List of Gocovri drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646456	ADAMAS PHARMA	Methods of administering amantadine	Jun, 2034 (11 years from now)
US10154971	ADAMAS PHARMA	Methods of administering amantadine	Dec, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 24, 2024

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 August, 2017

Treatment: Treatment of dyskinesia, decreasing off time, and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

41. List of Harvoni drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10039779	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jan, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039779 (Pediatric)	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jul, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Dosing Schedule (D)	Nov 15, 2022
Orphan Drug Exclusivity (ODE)	Apr 7, 2024
Pediatric Exclusivity (PED)	Oct 7, 2024

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Market Authorisation Date: 10 October, 2014

Treatment: For the treatment of genotype 1, 4, 5 or 6 chronic hepatitis c virus (hcv) infection; For the treatment of hepatitis c; For treatment-naive genotype 1 patients with chronic hepatitis c virus (hcv) infection for a duration of 8-weeks

Dosage: TABLET;ORAL

42. List of Hetlioz drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730910	VANDA PHARMS INC	Treatment of circadian rhythm disorders	May, 2034 (11 years from now)
US10610511	VANDA PHARMS INC	Method of treatment	Oct, 2034 (11 years from now)
US11141400	VANDA PHARMS INC	Method of treatment	Oct, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Dec 1, 2023
Orphan Drug Exclusivity (ODE)	Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 31 January, 2014

Treatment: Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food

Dosage: CAPSULE;ORAL

43. List of Hetlioz Lq drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730910	VANDA PHARMS INC	Treatment of circadian rhythm disorders	May, 2034 (11 years from now)
US11141400	VANDA PHARMS INC	Method of treatment	Oct, 2034 (11 years from now)
US10610511	VANDA PHARMS INC	Method of treatment	Oct, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Dec 1, 2023
Orphan Drug Exclusivity (ODE)	Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food

Dosage: SUSPENSION;ORAL

44. List of Ibrance drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10723730	PFIZER	Solid forms of a selective CDK4/6 inhibitor	Feb, 2034 (11 years from now)

Drugs and Companies using PALBOCICLIB ingredient

Market Authorisation Date: 01 November, 2019

Treatment: NA

Dosage: TABLET;ORAL

45. List of Idhifa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10093654	CELGENE CORP	Therapeutically active compounds and their methods of use	Aug, 2034 (11 years from now)
US9738625	CELGENE CORP	Therapeutically active compounds and their methods of use	Aug, 2034 (11 years from now)
US9732062	CELGENE CORP	Therapeutically active compounds and their methods of use	Sep, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 1, 2024
New Chemical Entity Exclusivity (NCE)	Aug 1, 2022

Drugs and Companies using ENASIDENIB MESYLATE ingredient

NCE-1 date: August, 2021

Market Authorisation Date: 01 August, 2017

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

46. List of Imbruvica drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9540382 (Pediatric)	PHARMACYCLICS INC	Crystalline forms of a Bruton's tyrosine kinase inhibitor	Feb, 2034 (11 years from now)
US9296753 (Pediatric)	PHARMACYCLICS INC	Crystalline forms of a Bruton's tyrosine kinase inhibitor	Apr, 2034 (11 years from now)
US10463668	PHARMACYCLICS INC	Methods of treating and preventing graft versus host disease	Oct, 2034 (11 years from now)
US10695350	PHARMACYCLICS INC	Methods of treating and preventing graft versus host disease	Oct, 2034 (11 years from now)
US9795604	PHARMACYCLICS INC	Methods of treating and preventing graft versus host disease	Oct, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
M	Jan 25, 2022
New Patient Population (NPP)	Aug 24, 2025
Orphan Drug Exclusivity (ODE)	Aug 2, 2024
Pediatric Exclusivity (PED)	Feb 24, 2026

Drugs and Companies using IBRUTINIB ingredient

Market Authorisation Date: 13 November, 2013

Treatment: Treatment of refractory chronic graft-versus-host disease; Treatment of chronic graft versus host disease refractory to systemic therapy; Treatment of pediatric patients age 1 year and older with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy

Dosage: CAPSULE;ORAL

47. List of Imcivree drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129869	RHYTHM	Pharmaceutical compositions	Jul, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 25, 2027
New Chemical Entity Exclusivity (NCE)	Nov 25, 2025
New Indication (I)	Jun 16, 2025

Drugs and Companies using SETMELANOTIDE ACETATE ingredient

NCE-1 date: November, 2024

Market Authorisation Date: 25 November, 2020

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

48. List of Imvexxy drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11266661	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Feb, 2034 (11 years from now)

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 29 May, 2018

Treatment: Treatment of dyspareunia; Treatment of a symptom of vulvar and vaginal atrophy

Dosage: INSERT;VAGINAL

49. List of Inomax drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9279794	MALLINCKRODT HOSP	Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide	Feb, 2034 (11 years from now)
US9279794 (Pediatric)	MALLINCKRODT HOSP	Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide	Aug, 2034 (11 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 23 December, 1999

Treatment: A method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient

Dosage: GAS;INHALATION

50. List of Jadenu drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9283209	NOVARTIS PHARMS CORP	Oral formulations of deferasirox	Nov, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
M	Jul 23, 2023

Drugs and Companies using DEFERASIROX ingredient

Market Authorisation Date: 30 March, 2015

Treatment: NA

Dosage: TABLET;ORAL

51. List of Jardiance drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US9949997	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	May, 2034 (11 years from now)
US9949998	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Jun, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Aug 18, 2024
M	Feb 24, 2025

Drugs and Companies using EMPAGLIFLOZIN ingredient

Market Authorisation Date: 01 August, 2014

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of 10 mg or 25 mg of empagliflozin; Method for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes mellitus and heart failure by once daily administration of empagliflozin; Method for reducing the risk of cardiovascular death plus hospitalization for heart failure in adults with type 2 diabetes mellitus, heart failure and reduced ejection fraction by once daily administration of empagliflozin

Dosage: TABLET;ORAL

52. List of Jublia drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10864274	BAUSCH	Stabilized efinaconazole formulations	Oct, 2034 (11 years from now)
US9662394	BAUSCH	Stabilized efinaconazole compositions	Oct, 2034 (11 years from now)
US10342875	BAUSCH	Stabilized efinaconazole compositions	Oct, 2034 (11 years from now)
US10828293	BAUSCH	Anti-infective methods, compositions, and devices	Oct, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Apr 27, 2023

Drugs and Companies using EFINACONAZOLE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes

Dosage: SOLUTION;TOPICAL

53. List of Kloxxado drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10722510	HIKMA	Liquid naloxone spray	Aug, 2034 (11 years from now)
US10973814	HIKMA	Liquid naloxone spray	Aug, 2034 (11 years from now)
US11135155	HIKMA	Liquid naloxone spray	Aug, 2034 (11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 April, 2021

Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients

Dosage: SPRAY;NASAL

54. List of Leqvio drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10125369	NOVARTIS	PCSK9 iRNA compositions and methods of use thereof	Aug, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: December, 2025

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene

Dosage: SOLUTION;SUBCUTANEOUS

55. List of Liletta drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028858	MEDICINES360	Intrauterine systems, IUD insertion devices, and related methods and kits therefor	Mar, 2034 (11 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 26 February, 2015

Treatment: A method for prevention of pregnancy

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

56. List of Lonsurf drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10457666	TAIHO ONCOLOGY	Stable crystal form of tipiracil hydrochloride and crystallization method for the same	Jun, 2034 (11 years from now)
US9527833	TAIHO ONCOLOGY	Stable crystal form of tipiracil hydrochloride and crystallization method for the same	Jun, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Feb 22, 2022
Orphan Drug Exclusivity (ODE)	Feb 22, 2026

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

Market Authorisation Date: 22 September, 2015

Treatment: NA

Dosage: TABLET;ORAL

57. List of Loreev Xr drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8999393	ALMATICA	Sustained release formulations of lorazepam	Jan, 2034 (10 years from now)

Drugs and Companies using LORAZEPAM ingredient

Market Authorisation Date: 27 August, 2021

Treatment: Once daily treatment of anxiety disorder in adults

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

58. List of Luzu drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980931	BAUSCH	Method of evaluating pharmaceutical preparation containing luliconazole and index substance	Apr, 2034 (11 years from now)

Drugs and Companies using LULICONAZOLE ingredient

Market Authorisation Date: 14 November, 2013

Treatment: NA

Dosage: CREAM;TOPICAL

59. List of Makena drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789257	COVIS	Needle assisted injection device having reduced trigger force	Feb, 2034 (11 years from now)

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Market Authorisation Date: 03 February, 2011

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS

60. List of Mavyret drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10286029	ABBVIE INC	Method for treating HCV	Mar, 2034 (11 years from now)
US11484534	ABBVIE INC	Methods for treating HCV	Mar, 2034 (11 years from now)
US10286029 (Pediatric)	ABBVIE INC	Method for treating HCV	Sep, 2034 (11 years from now)
US11484534 (Pediatric)	ABBVIE INC	Methods for treating HCV	Sep, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 3, 2022
New Patient Population (NPP)	Apr 30, 2022
Orphan Drug Exclusivity (ODE)	Jun 10, 2028
New Dosing Schedule (D)	Sep 26, 2022
M	Apr 10, 2023
Pediatric Exclusivity (PED)	Feb 3, 2023

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 03 August, 2017

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg

Dosage: TABLET;ORAL

61. List of Morphine Sulfate drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248229	FRESENIUS KABI USA	Packaging system for oxygen-sensitive drugs	Mar, 2034 (11 years from now)
US9192608	FRESENIUS KABI USA	Morphine formulations	Mar, 2034 (11 years from now)
US9072781	FRESENIUS KABI USA	Morphine formulations	Mar, 2034 (11 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Market Authorisation Date: 30 October, 2013

Treatment: Management of chronic pain in patients requiring opioid analgesia; Treatment of pain

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS

62. List of Natesto drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090312	ACERUS	Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event	Mar, 2034 (11 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 28 May, 2014

Treatment: Nasal administration of a testosterone gel to a patient to treat the patient for a condition associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;NASAL

63. List of Omidria drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486406 (Pediatric)	RAYNER SURGICAL	Stable preservative-free mydriatic and anti-inflammatory solutions for injection	Apr, 2034 (11 years from now)
US9066856 (Pediatric)	RAYNER SURGICAL	Stable preservative-free mydriatic and anti-inflammatory solutions for injection	Apr, 2034 (11 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 May, 2014

Treatment: NA

Dosage: SOLUTION;IRRIGATION

64. List of Onzetra Xsail drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076614	CURRAX	Nasal delivery devices	Oct, 2034 (11 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: NA

Dosage: POWDER;NASAL

65. List of Oriahnn (copackaged) drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10881659	ABBVIE INC	Methods of treating heavy menstrual bleeding	Mar, 2034 (11 years from now)
US11045470	ABBVIE INC	Methods of treating heavy menstrual bleeding	Mar, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 23, 2023
New Product (NP)	May 29, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 29 May, 2020

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)

Dosage: CAPSULE;ORAL

66. List of Orilissa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11344551	ABBVIE INC	Methods of treating heavy menstrual bleeding	Mar, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 23 July, 2018

Treatment: Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women to reduce dysmenorrhea and non-menstrual pelvic pain; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women having dyspareunia associated with endometriosis

Dosage: TABLET;ORAL

67. List of Otezla drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10092541	AMGEN INC	Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast	May, 2034 (11 years from now)
US9872854	AMGEN INC	Methods for the treatment of psoriatic arthritis using apremilast	May, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Dec 20, 2024
Orphan Drug Exclusivity (ODE)	Jul 19, 2026
M	Apr 10, 2023

Drugs and Companies using APREMILAST ingredient

Market Authorisation Date: 21 March, 2014

Treatment: Treatment of psoriasis using a dosage titration schedule; Treatment of adult patients with oral ulcers associated with behcet's disease using a dosage titration schedule; Treatment of psoriatic arthritis using a dosage titration schedule; Treatment of psoriatic arthritis with apremilast using a dosage titration schedule and a second active agent

Dosage: TABLET;ORAL

68. List of Oxbryta drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248199	GLOBAL BLOOD THERAPS	1:1 adducts of sickle hemoglobin	Jan, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 25, 2024

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 17 December, 2021

Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 1; Treatment of sickle cell disease by administering voxelotor, as recited in claim 2

Dosage: TABLET, FOR SUSPENSION;ORAL

69. List of Oxlumo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11060093	ALNYLAM PHARMS INC	Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Dec, 2034 (11 years from now)
US10465195	ALNYLAM PHARMS INC	Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Dec, 2034 (11 years from now)
US9828606	ALNYLAM PHARMS INC	Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Dec, 2034 (11 years from now)
US10487330	ALNYLAM PHARMS INC	Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Dec, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435692	ALNYLAM PHARMS INC	Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Dec, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 23, 2027
New Chemical Entity Exclusivity (NCE)	Nov 23, 2025
New Indication (I)	Oct 6, 2025

Drugs and Companies using LUMASIRAN SODIUM ingredient

NCE-1 date: November, 2024

Market Authorisation Date: 23 November, 2020

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

70. List of Parsabiv drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9820938	KAI PHARMS INC	Stable liquid formulation of AMG 416 (etelcalcetide)	Jun, 2034 (11 years from now)
US10344765	KAI PHARMS INC	Stable liquid formulation of AMG 416 (etelcalcetide)	Jun, 2034 (11 years from now)
US11162500	KAI PHARMS INC	Stable liquid formulation of AMG 416 (etelcalcetide)	Jun, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 7, 2022

Drugs and Companies using ETELCALCETIDE ingredient

NCE-1 date: February, 2021

Market Authorisation Date: 07 February, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

71. List of Pluvicto drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10398791	AAA USA NOVARTIS	Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer	Oct, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 23, 2027

Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient

NCE-1 date: March, 2026

Market Authorisation Date: 23 March, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

72. List of Procysbi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173851	HORIZON	Delayed release cysteamine bead formulation, and methods of making and using same	Jun, 2034 (11 years from now)
US9233077	HORIZON	Delayed release cysteamine bead formulation, and methods of making and using same	Jun, 2034 (11 years from now)
US9173851 (Pediatric)	HORIZON	Delayed release cysteamine bead formulation, and methods of making and using same	Dec, 2034 (11 years from now)
US9233077 (Pediatric)	HORIZON	Delayed release cysteamine bead formulation, and methods of making and using same	Dec, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 22, 2024
Pediatric Exclusivity (PED)	Feb 14, 2023

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Market Authorisation Date: 30 April, 2013

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

73. List of Procysbi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233077	HORIZON PHARMA USA	Delayed release cysteamine bead formulation, and methods of making and using same	Jun, 2034 (11 years from now)
US9173851	HORIZON PHARMA USA	Delayed release cysteamine bead formulation, and methods of making and using same	Jun, 2034 (11 years from now)
US9233077 (Pediatric)	HORIZON PHARMA USA	Delayed release cysteamine bead formulation, and methods of making and using same	Dec, 2034 (11 years from now)
US9173851 (Pediatric)	HORIZON PHARMA USA	Delayed release cysteamine bead formulation, and methods of making and using same	Dec, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 22, 2024
Pediatric Exclusivity (PED)	Feb 14, 2023

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Market Authorisation Date: 14 February, 2020

Treatment: NA

Dosage: GRANULE, DELAYED RELEASE;ORAL

74. List of Quviviq drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9790208	IDORSIA	Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist	Dec, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10023560	IDORSIA	Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist	Dec, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 7, 2027

Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient

NCE-1 date: April, 2026

Market Authorisation Date: 07 April, 2022

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

75. List of Rayaldee drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357502	EIRGEN	Stabilized modified release vitamin D formulation and method of administering same	Mar, 2034 (11 years from now)
US11253528	EIRGEN	Stabilized modified release Vitamin D formulation and method of administering same	Mar, 2034 (11 years from now)
US9861644	EIRGEN	Stabilized modified release vitamin D formulation and method of administering same	Mar, 2034 (11 years from now)
US10300078	EIRGEN	Stabilized modified release vitamin D formulation and method of administering same	Mar, 2034 (11 years from now)

Drugs and Companies using CALCIFEDIOL ingredient

Market Authorisation Date: 17 June, 2016

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

76. List of Restasis drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9676525	ALLERGAN	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids	Feb, 2034 (11 years from now)
US9669974	ALLERGAN	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids	May, 2034 (11 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 December, 2002

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

77. List of Rhopressa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9931336	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
US10588901	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
US9415043	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11185538	AERIE PHARMS INC	Compositions for treating glaucoma or reducing intraocular pressure	Mar, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 18, 2022

Drugs and Companies using NETARSUDIL MESYLATE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 18 December, 2017

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

78. List of Rocklatan drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9415043	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
US9993470	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
US9931336	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
US10588901	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11197853	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
US11185538	AERIE PHARMS INC	Compositions for treating glaucoma or reducing intraocular pressure	Mar, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 18, 2022
New Combination (NC)	Mar 12, 2022

Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 12 March, 2019

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

79. List of Ryaltris drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561672	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)
US11400101	GLENMARK SPECIALTY	Treatment of allergic rhinitis using a combination of mometasone and olopatadine	Sep, 2034 (11 years from now)
US10765686	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)
US10758550	GLENMARK SPECIALTY	Treatment of allergic rhinitis using a combination of mometasone and olopatadine	Sep, 2034 (11 years from now)
US10646500	GLENMARK SPECIALTY	Treatment of allergic rhinitis using a combination of mometasone and olopatadine	Sep, 2034 (11 years from now)
US10548907	GLENMARK SPECIALTY	Treatment of allergic rhinitis using a combination of mometasone and olopatadine	Sep, 2034 (11 years from now)
US10016443	GLENMARK SPECIALTY	Treatment of allergic rhinitis using a combination of mometasone and olopatadine	Sep, 2034 (11 years from now)
US10517880	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)
US9750754	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)
US9078923	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)
US9937189	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)
US10376526	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)
US9370483	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Jan 13, 2025

Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 January, 2022

Treatment: Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate; Method of delivering a combination of olopatadine hydrochloride and mometasone furoate to a nasal airway; Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate to a pediatric patient

Dosage: SPRAY, METERED;NASAL

80. List of Rybelsus drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10278923	NOVO	Oral dosing of GLP-1 compounds	May, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
M	Jan 16, 2023
New Product (NP)	Sep 20, 2022
New Chemical Entity Exclusivity (NCE)	Dec 5, 2022

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 20 September, 2019

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET;ORAL

81. List of Sinuva drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10406332	INTERSECT ENT INC	Systems, devices, and method for treating a sinus condition	Mar, 2034 (11 years from now)
US10232152	INTERSECT ENT INC	Systems, devices, and method for treating a sinus condition	Nov, 2034 (11 years from now)

Drugs and Companies using MOMETASONE FUROATE ingredient

Market Authorisation Date: 08 December, 2017

Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant

Dosage: IMPLANT;IMPLANTATION

82. List of Soolantra drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233118	GALDERMA LABS LP	Treatment of papulopustular rosacea with ivermectin	Mar, 2034 (11 years from now)
US9089587	GALDERMA LABS LP	Treatment of papulopustular rosacea with ivermectin	Mar, 2034 (11 years from now)
US9233117	GALDERMA LABS LP	Treatment of inflammatory lesions of rosacea with ivermectin	Mar, 2034 (11 years from now)
US9782425	GALDERMA LABS LP	Treatment of papulopustular rosacea with ivermectin	Mar, 2034 (11 years from now)
US10206939	GALDERMA LABS LP	Treatment of papulopustular rosacea with ivermectin	Mar, 2034 (11 years from now)

Drugs and Companies using IVERMECTIN ingredient

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of inflammatory lesions of rosacea.

Dosage: CREAM;TOPICAL

83. List of Sotylize drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11013703	AZURITY	Sotalol compositions and uses of the same	Apr, 2034 (11 years from now)
US10206895	AZURITY	Sotalol compositions and uses of the same	Apr, 2034 (11 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 October, 2014

Treatment: Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm; Indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening

Dosage: SOLUTION;ORAL

84. List of Spinraza drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9926559	BIOGEN IDEC	Compositions and methods for modulation of SMN2 splicing in a subject	Jan, 2034 (10 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 23, 2023

Drugs and Companies using NUSINERSEN SODIUM ingredient

Market Authorisation Date: 23 December, 2016

Treatment: Treatment of spinal muscular atrophy

Dosage: SOLUTION;INTRATHECAL

85. List of Spravato drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446260	JANSSEN PHARMS	Pharmaceutical composition of S-ketamine hydrochloride	Mar, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 5, 2024
New Indication (I)	Jul 31, 2023

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 March, 2019

Treatment: Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition twice per week in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine twice per week as a pharmaceutical composition in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition in conjunction with an oral antidepressant

Dosage: SPRAY;NASAL

86. List of Spritam drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160786	APRECIA PHARMS	Rapid disperse dosage form	Mar, 2034 (11 years from now)
US9669009	APRECIA PHARMS	Rapid disperse dosage form containing levetiracetam	Mar, 2034 (11 years from now)
US9339489	APRECIA PHARMS	Rapid disperse dosage form containing levetiracetam	Mar, 2034 (11 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 31 July, 2015

Treatment: Method of administering levetiracetam under fasted conditions; Method of administering levetiracetam; Method of administering levetiracetam under fed conditions

Dosage: TABLET, FOR SUSPENSION;ORAL

87. List of Sunosi drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439597	AXSOME MALTA	Formulations of (R)-2-amino-3-phenylpropyl carbamate	Nov, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 17, 2024
Orphan Drug Exclusivity (ODE)	Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: NA

Dosage: TABLET;ORAL

88. List of Synjardy drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 26 August, 2015

Treatment: Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin

Dosage: TABLET;ORAL

89. List of Synjardy Xr drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US9949998	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Jun, 2034 (11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 09 December, 2016

Dosage: TABLET, EXTENDED RELEASE;ORAL

90. List of Talicia drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050263	REDHILL	Pharmaceutical compositions for the treatment of Helicobacter pylori	Feb, 2034 (11 years from now)
US11135172	REDHILL	Rifabutin-based compositions and methods for treating Helicobacter pylori infection	Feb, 2034 (11 years from now)
US9498445	REDHILL	Pharmaceutical compositions for the treatment of Helicobacter pylori	Feb, 2034 (11 years from now)
US10238606	REDHILL	Pharmaceutical compositions for the treatment of Helicobacter pylori	Feb, 2034 (11 years from now)
US9603806	REDHILL	Pharmaceutical compositions for the treatment of Helicobacter pylori	Feb, 2034 (11 years from now)

Drugs and Companies using AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN ingredient

Market Authorisation Date: 01 November, 2019

Treatment: Treatment of h. pylori infection in adults

Dosage: CAPSULE, DELAYED RELEASE;ORAL

91. List of Tazverik drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8410088	EPIZYME INC	Aryl- or heteroaryl-substituted benzene compounds	Aug, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9688665	EPIZYME INC	Methods of treating cancer	Aug, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 23, 2025
New Indication (I)	Jun 18, 2023
Orphan Drug Exclusivity (ODE)	Jan 23, 2027

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

NCE-1 date: January, 2024

Market Authorisation Date: 23 January, 2020

Treatment: Method of treating epithelioid sarcoma

Dosage: TABLET;ORAL

92. List of Tembexa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8962829	CHIMERIX	Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof	Oct, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10112909	CHIMERIX	Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof	Oct, 2034 (11 years from now)
US10487061	CHIMERIX	Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof	Oct, 2034 (11 years from now)
US9371344	CHIMERIX	Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof	Oct, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Jun 4, 2024
Orphan Drug Exclusivity (ODE)	Jun 4, 2028

Drugs and Companies using BRINCIDOFOVIR ingredient

Market Authorisation Date: 04 June, 2021

Treatment: Method of treating human smallpox disease

Dosage: TABLET;ORAL

93. List of Trijardy Xr drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US9949998	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Jun, 2034 (11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 January, 2020

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin, linagliptin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr <30 ml/min/1.73 m2; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin in combination with linagliptin and metformin

Dosage: TABLET, EXTENDED RELEASE;ORAL

94. List of Trulance drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10011637	SALIX	Ultra-pure agonists of guanylate cyclase C, method of making and using same	Jun, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11142549	SALIX	Ultra-pure agonists of guanylate cyclase C, method of making and using same	Jun, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 19, 2022

Drugs and Companies using PLECANATIDE ingredient

NCE-1 date: January, 2021

Market Authorisation Date: 19 January, 2017

Treatment: NA

Dosage: TABLET;ORAL

95. List of Truseltiq drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160804	HELSINN HLTHCARE	Pharmaceutical dosage forms	Dec, 2034 (11 years from now)
US10278969	HELSINN HLTHCARE	Pharmaceutical dosage forms	Dec, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 28, 2026
Orphan Drug Exclusivity (ODE)	May 28, 2028

Drugs and Companies using INFIGRATINIB PHOSPHATE ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: NA

Dosage: CAPSULE;ORAL

96. List of Velphoro drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234938	VIFOR FRESENIUS	Pharmaceutical composition, comprising phosphate binder particles	Nov, 2034 (11 years from now)
US11446252	VIFOR FRESENIUS	Pharmaceutical composition, comprising phosphate binder particles	Nov, 2034 (11 years from now)
US10624855	VIFOR FRESENIUS	Pharmaceutical composition, comprising phosphate binder particles	Nov, 2034 (11 years from now)

Drugs and Companies using FERRIC OXYHYDROXIDE ingredient

Market Authorisation Date: 27 November, 2013

Treatment: NA

Dosage: TABLET, CHEWABLE;ORAL

97. List of Vogelxo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295675	UPSHER SMITH LABS	Testosterone gel compositions and related methods	Feb, 2034 (11 years from now)
US9662340	UPSHER SMITH LABS	Testosterone gel compositions and related methods	Feb, 2034 (11 years from now)
US8785426	UPSHER SMITH LABS	Testosterone gel compositions and related methods	Feb, 2034 (11 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 04 June, 2014

Treatment: Method for transdermal delivery of testosterone

Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL

98. List of Vosevi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9296782	GILEAD SCIENCES INC	Inhibitors of hepatitis C virus	Jul, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11116783	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jan, 2034 (11 years from now)
US11116783 (Pediatric)	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jul, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 18, 2022

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

NCE-1 date: July, 2021

Market Authorisation Date: 18 July, 2017

Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor

Dosage: TABLET;ORAL

99. List of Vyxeos drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028912	CELATOR PHARMS	Method of lyophilizing liposomes	Sep, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Aug 3, 2024
New Patient Population (NPP)	Mar 30, 2024

Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient

Market Authorisation Date: 03 August, 2017

Treatment: Method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older; Method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older

Dosage: POWDER;INTRAVENOUS

100. List of Welireg drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9969689	MERCK SHARP DOHME	Aryl ethers and uses thereof	Sep, 2034 (11 years from now)
US9908845	MERCK SHARP DOHME	Aryl ethers and uses thereof	Sep, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 13, 2026
Orphan Drug Exclusivity (ODE)	Aug 13, 2028

Drugs and Companies using BELZUTIFAN ingredient

NCE-1 date: August, 2025

Market Authorisation Date: 13 August, 2021

Treatment: Treatment of adult patients with von hippel-lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery

Dosage: TABLET;ORAL

101. List of Xarelto drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539218	JANSSEN PHARMS	Prevention and treatment of thromboembolic disorders	Feb, 2034 (11 years from now)
US9539218 (Pediatric)	JANSSEN PHARMS	Prevention and treatment of thromboembolic disorders	Aug, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Aug 23, 2024
M	Mar 10, 2023
Pediatric Exclusivity (PED)	Apr 11, 2023

Drugs and Companies using RIVAROXABAN ingredient

Market Authorisation Date: 01 July, 2011

Treatment: Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days; Treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days; Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days; Reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days; Prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding with once daily, rapid-release tablet administered for at least 5 consecutive days; Treatment of dvt and/or pe and reduction in the risk of recurrent dvt and/or pe in pediatric patients (>=50 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; After completion of initial treatment lasting at least 6 months, to reduce the risk of recurrence of deep vein thrombosis and/or pulmonary embolism in certain patients with once daily, rapid-release tablet administered for at least 5 consecutive days; Prophylaxis of pe, dvt and/or stroke in pediatric patients (>=50 kg) aged 2 years and older with congenital heart disease after fontan procedure with once daily, rapid-release tablet administered for at least 5 consecutive days; Treatment of dvt and/or pe and reduction in risk of recurrent dvt and/or pe in pediatric patients (30-49.9 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment

Dosage: TABLET;ORAL

102. List of Xeglyze drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10292389	DR REDDYS LABS SA	Pediculicidal composition	Dec, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 24, 2025

Drugs and Companies using ABAMETAPIR ingredient

NCE-1 date: July, 2024

Market Authorisation Date: 24 July, 2020

Treatment: Topical treatment of head lice infestation in patients 6 months of age and older

Dosage: LOTION;TOPICAL

103. List of Xeljanz Xr drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10639309	PFIZER	Tofacitinib oral sustained release dosage forms	Mar, 2034 (11 years from now)
US9937181	PFIZER	Tofacitinib oral sustained release dosage forms	Mar, 2034 (11 years from now)
US11253523	PFIZER	Tofacitinib oral sustained release dosage forms	Mar, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Dec 14, 2024

Drugs and Companies using TOFACITINIB CITRATE ingredient

Market Authorisation Date: 23 February, 2016

Treatment: A method of treating ankylosing spondylitis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, and 87-98; A method of treating psoriatic arthritis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-44, 46, 48, 50, 53, 59, 62, 68-71, 73, 76, 82-84, and 87-98; A method of treating rheumatoid arthritis by administering the formulation of tofacitinib of claims 1, 2, 8, 9, 15-21, 27-31, 34-43, 50, 51, 59, 60, 68-71, 73, 74, 82-84 and 87-98; A method of treating ulcerative colitis, by administering the formulation of tofacitinib of claims 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 and 87-98

Dosage: TABLET, EXTENDED RELEASE;ORAL

104. List of Xhance drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076614	OPTINOSE US INC	Nasal delivery devices	Oct, 2034 (11 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 18 September, 2017

Treatment: NA

Dosage: SPRAY, METERED;NASAL

105. List of Xipere drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937075	BAUSCH AND LOMB INC	Apparatus and methods for ocular injection	May, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Oct 22, 2024

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 22 October, 2021

Treatment: NA

Dosage: SUSPENSION;INJECTION

106. List of Xyosted (autoinjector) drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10881798	ANTARES PHARMA INC	Needle assisted injection device having reduced trigger force	Feb, 2034 (11 years from now)
US11160751	ANTARES PHARMA INC	Hematocrit modulation through needle assisted jet injection of testosterone	Oct, 2034 (11 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION;SUBCUTANEOUS

107. List of Yonsa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9889144	SUN PHARM	Abiraterone acetate formulation and methods of use	Mar, 2034 (11 years from now)
US10292990	SUN PHARM	Abiraterone steroid formulation	May, 2034 (11 years from now)

Drugs and Companies using ABIRATERONE ACETATE ingredient

Market Authorisation Date: 22 May, 2018

Treatment: Use in combination with methylprednisolone for the treatment of patients with prostate cancer

Dosage: TABLET;ORAL

108. List of Zerbaxa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8906898	CUBIST PHARMS LLC	Solid forms of ceftolozane	May, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278622	CUBIST PHARMS LLC	Ceftolozane antibiotic compositions	Mar, 2034 (11 years from now)
US8968753	CUBIST PHARMS LLC	Ceftolozane-tazobactam pharmaceutical compositions	Mar, 2034 (11 years from now)
US10420841	CUBIST PHARMS LLC	Ceftolozane antibiotic compositions	Mar, 2034 (11 years from now)
US9872906	CUBIST PHARMS LLC	Ceftolozane antibiotic compositions	Mar, 2034 (11 years from now)
US9320740	CUBIST PHARMS LLC	Ceftolozane-tazobactam pharmaceutical compositions	Mar, 2034 (11 years from now)
US10933053	CUBIST PHARMS LLC	Treating infections with ceftolozane/tazobactam in subjects having impaired renal function	Sep, 2034 (11 years from now)
US10376496	CUBIST PHARMS LLC	Treating infections with ceftolozane/tazobactam in subjects having impaired renal function	Sep, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 19, 2019
New Patient Population (NPP)	Apr 21, 2025
Generating Antibiotic Incentives Now (GAIN)	Dec 19, 2024

Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient

NCE-1 date: December, 2023

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of hospital-acquired bacterial pneumonia (habp); Treatment of ventilator-associated bacterial pneumonia (vabp); Treatment of complicated urinary tract infection, including pyelonephritis; Treatment of complicated intra-abdominal infection; Treatment of complicated urinary tract infection; Treatment of ventilator-associated bacterial pneumonia in patients with end-stage renal disease on hemodialysis; Treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease on hemodialysis; Treatment of complicated urinary tract infection in patients with end-stage renal disease on hemodialysis; Treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis

Dosage: POWDER;INTRAVENOUS

109. List of Zohydro Er drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9713611	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (11 years from now)
US9452163	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (11 years from now)
US9486451	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (11 years from now)
US10092559	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (11 years from now)
US9132096	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (11 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 25 October, 2013

Treatment: Treatment of pain

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

110. List of Zuragard drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688291	ZUREX PHARMA	Medical skin applicator apparatus	Dec, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Apr 26, 2022
M	Jun 24, 2024

Drugs and Companies using ISOPROPYL ALCOHOL ingredient

Market Authorisation Date: 26 April, 2019

Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery

Dosage: SOLUTION;TOPICAL

111. List of Zynrelef Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9913909	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (11 years from now)
US11253504	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (11 years from now)
US10398686	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (11 years from now)
US9744163	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (11 years from now)
US9592227	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	May 12, 2024

Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient

Market Authorisation Date: 12 May, 2021

Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation

Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR

availability in other generic markets.

Click on the highlighted region to filter.

List of large molecules

1. List of Lucentis large molecules

Patent Number	Company	Patent Title	Patent Expiry
US9765379	GENENTECH, INC.	Harvest operations for recombinant proteins	Mar, 2034 (11 years from now)
US10829732	GENENTECH, INC.	Cell culture compositions with antioxidants and methods for polypeptide production	Mar, 2034 (11 years from now)
US10017732	GENENTECH, INC.	Cell culture compositions with antioxidants and methods for polypeptide production	Mar, 2034 (11 years from now)

Ingredients: RANIBIZUMAB

2. List of Humira large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US9499614	ABBVIE INC.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides	Mar, 2034 (11 years from now)
US9550826	ABBVIE INC.	Glycoengineered binding protein compositions	Nov, 2034 (11 years from now)

Ingredients: ADALIMUMAB

3. List of Avastin large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US10676710	GENENTECH, INC.	Cell culture compositions with antioxidants and methods for polypeptide production	Mar, 2034 (11 years from now)
US9441035	GENENTECH, INC.	Cell culture media and methods of antibody production	Apr, 2034 (11 years from now)

Ingredients: BEVACIZUMAB

4. List of Eylea large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US11332771	REGENERON PHARMACEUTICALS, INC.	Serum-free cell culture medium	Mar, 2034 (11 years from now)
USD858754	REGENERON PHARMACEUTICALS, INC.	Syringe cap	Sep, 2034 (11 years from now)

Ingredients: AFLIBERCEPT

5. List of Tysabri large molecules

Patent Number	Company	Patent Title	Patent Expiry
US10677803	BIOGEN INC.	Method of assessing risk of PML	May, 2034 (11 years from now)
US11280794	BIOGEN INC.	Method of assessing risk of PML	May, 2034 (11 years from now)
US10119976	BIOGEN INC.	Method of assessing risk of PML	May, 2034 (11 years from now)
US10676772	BIOGEN INC.	Control of protein glycosylation by culture medium supplementation and cell culture process parameters	Aug, 2034 (11 years from now)
US9994968	BIOGEN INC.	Electrochemical etching apparatus	Aug, 2034 (11 years from now)

Ingredients: NATALIZUMAB

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in

Drugs expiring in 2035

Drug information about Solosec

Strength	Dosage	Availability
0.2MG/ML	INJECTABLE;INJECTION	Prescription
1MG/ML	INJECTABLE;INJECTION	Prescription
2MG/ML	INJECTABLE;INJECTION	Prescription
4MG/ML	INJECTABLE;INJECTION	Discontinued
10MG/ML	INJECTABLE;INJECTION	Discontinued
250MG/VIAL	INJECTABLE;INJECTION	Discontinued

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
75 mg and 100 mg	05 Feb, 2009	1	28 Dec, 2010	15 Dec, 2022	Eligible
150 mg	19 Dec, 2008	1		15 Dec, 2022	Extinguished
200 mg	19 May, 2014	1	19 May, 2016	15 Dec, 2022	Eligible
80 mg	01 Jul, 2015	1	29 Apr, 2016	15 Dec, 2022	Eligible
50 mg	05 Nov, 2015	1	23 May, 2016	03 Feb, 2028	Eligible
60 mg and 120 mg	28 Sep, 2017	1		23 Dec, 2034

Strength	Dosage	Availability
EQ 50MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 75MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 80MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 100MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 150MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 200MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 60MG BASE	TABLET, DELAYED RELEASE;ORAL	Discontinued
EQ 120MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
200MG;50MG	TABLET;ORAL	Prescription
400MG;100MG	TABLET;ORAL	Prescription

Strength	Dosage	Availability
10MG/10ML (1MG/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	Prescription
1MG/ML (1MG/ML)	SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS	Prescription

Strength	Dosage	Availability
100MG/2ML (50MG/ML)	SOLUTION;INTRAVENOUS	Prescription
500MG/10ML (50MG/ML)	SOLUTION;INTRAVENOUS	Prescription

Strength	Dosage	Availability
EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	SOLUTION;INTRAVENOUS	Discontinued

Strength	Dosage	Availability
10MG;5MG	TABLET;ORAL	Prescription
25MG;5MG	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
137 mg	16 Jan, 2018	1		02 Dec, 2030
68.5 mg	30 Apr, 2020	1		04 Dec, 2034

Strength	Dosage	Availability
EQ 68.5MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 137MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
45MG;200MG	TABLET;ORAL	Prescription
90MG;400MG	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
75 mg, 100 mg and 125 mg	04 Feb, 2019	12		22 Jan, 2023
75 mg, 100 mg and 125 mg	24 Nov, 2020	1		28 Feb, 2034

Strength	Dosage	Availability
75MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription
125MG	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
70 mg	14 Dec, 2018	1	31 Mar, 2021	30 Oct, 2033	Eligible
140 mg	13 Nov, 2017	8	31 Mar, 2021	24 Oct, 2034	Deferred
140 mg and 560 mg	05 Nov, 2018	1		03 Mar, 2036
280 mg and 420 mg	14 Dec, 2018	1		03 Mar, 2036

Strength	Dosage	Availability
0.004MG	INSERT;VAGINAL	Prescription
0.01MG	INSERT;VAGINAL	Prescription

Strength	Dosage	Availability
100PPM	GAS;INHALATION	Discontinued
800PPM	GAS;INHALATION	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
90 mg and 360 mg	19 Oct, 2015	1		05 Apr, 2019	Extinguished
180 mg	21 Apr, 2016	1	13 Dec, 2019	21 Nov, 2034	Eligible

Strength	Dosage	Availability
EQ 6.14MG BASE;15MG	TABLET;ORAL	Prescription
EQ 8.19MG BASE;20MG	TABLET;ORAL	Prescription

Strength	Dosage	Availability
1250MG/5ML (250MG/ML)	SOLUTION;INTRAMUSCULAR	Prescription
250MG/ML (250MG/ML)	SOLUTION;INTRAMUSCULAR	Prescription
275MG/1.1ML (250MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

Strength	Dosage	Availability
2MG/ML (2MG/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	Prescription
4MG/ML (4MG/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	Prescription
5MG/ML (5MG/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	Prescription
8MG/ML (8MG/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	Prescription
10MG/ML (10MG/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	Prescription

Pharsight

Drug Patents Expiring in 2034

1. List of Abilify Maintena Kit drug patents

2. List of Abraxane drug patents

3. List of Adempas drug patents

4. List of Airduo Digihaler drug patents

5. List of Alkindi Sprinkle drug patents

6. List of Alunbrig drug patents

7. List of Arikayce Kit drug patents

8. List of Aubagio drug patents

9. List of Austedo drug patents

10. List of Auvelity drug patents

11. List of Ayvakit drug patents

12. List of Barhemsys drug patents

13. List of Bosulif drug patents

14. List of Brukinsa drug patents

15. List of Camzyos drug patents

16. List of Caplyta drug patents

17. List of Cibinqo drug patents

18. List of Clenpiq drug patents

19. List of Contrave drug patents

20. List of Cosela drug patents

21. List of Cotellic drug patents

22. List of Dexycu Kit drug patents

23. List of Dificid drug patents

24. List of Dilaudid drug patents

25. List of Doryx drug patents

26. List of Durysta drug patents

27. List of Epclusa drug patents

28. List of Epinephrine drug patents

29. List of Evomela drug patents

30. List of Evzio drug patents

31. List of Evzio (autoinjector) drug patents

32. List of Exondys 51 drug patents

33. List of Firdapse drug patents

34. List of Fulvestrant drug patents

35. List of Furoscix drug patents

36. List of Ganzyk-rtu drug patents

37. List of Giapreza drug patents

38. List of Givlaari drug patents

39. List of Glyxambi drug patents

40. List of Gocovri drug patents

41. List of Harvoni drug patents

42. List of Hetlioz drug patents

43. List of Hetlioz Lq drug patents

44. List of Ibrance drug patents

45. List of Idhifa drug patents

46. List of Imbruvica drug patents

47. List of Imcivree drug patents

48. List of Imvexxy drug patents

49. List of Inomax drug patents

50. List of Jadenu drug patents

51. List of Jardiance drug patents

52. List of Jublia drug patents

53. List of Kloxxado drug patents

54. List of Leqvio drug patents

55. List of Liletta drug patents

56. List of Lonsurf drug patents

57. List of Loreev Xr drug patents

58. List of Luzu drug patents

59. List of Makena drug patents

60. List of Mavyret drug patents

61. List of Morphine Sulfate drug patents

62. List of Natesto drug patents

63. List of Omidria drug patents

64. List of Onzetra Xsail drug patents

65. List of Oriahnn (copackaged) drug patents

66. List of Orilissa drug patents

67. List of Otezla drug patents

68. List of Oxbryta drug patents

69. List of Oxlumo drug patents

70. List of Parsabiv drug patents

71. List of Pluvicto drug patents

72. List of Procysbi drug patents

73. List of Procysbi drug patents

74. List of Quviviq drug patents

75. List of Rayaldee drug patents

76. List of Restasis drug patents

77. List of Rhopressa drug patents

78. List of Rocklatan drug patents

Strength	Dosage	Availability
2.5MG/0.5ML (2.5MG/0.5ML)	SOLUTION;INTRAVENOUS	Prescription
5MG/ML (5MG/ML)	SOLUTION;INTRAVENOUS	Prescription
10MG/2ML (5MG/ML)	SOLUTION;INTRAVENOUS	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg and 75 mg	11 May, 2020	1		16 Aug, 2036
75 mg/Packet and 300 mg/Packet	16 Dec, 2021	1		16 Aug, 2036

Strength	Dosage	Availability
EQ 25MG BASE	CAPSULE, DELAYED RELEASE;ORAL	Prescription
EQ 75MG BASE	CAPSULE, DELAYED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
EQ 75MG BASE/PACKET	GRANULE, DELAYED RELEASE;ORAL	Prescription
EQ 300MG BASE/PACKET	GRANULE, DELAYED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
1GM	TABLET, FOR SUSPENSION;ORAL	Prescription
250MG	TABLET, FOR SUSPENSION;ORAL	Prescription
500MG	TABLET, FOR SUSPENSION;ORAL	Prescription
750MG	TABLET, FOR SUSPENSION;ORAL	Prescription

Strength	Dosage	Availability
5MG;1GM	TABLET;ORAL	Prescription
5MG;500MG	TABLET;ORAL	Prescription
12.5MG;1GM	TABLET;ORAL	Prescription
12.5MG;500MG	TABLET;ORAL	Prescription

Strength	Dosage	Availability
5MG;2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
10MG;5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
12.5MG;2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
25MG;5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
12.5MG/1.25GM ACTUATION	GEL, METERED;TRANSDERMAL	Prescription
50MG/5GM PACKET	GEL;TRANSDERMAL	Prescription

Strength	Submission Date	ANDA(s) Filed	Last patent expiry
2.5 mg	19 Nov, 2018	4	13 Nov, 2024
10 mg, 15 mg, and 20 mg	01 Jul, 2015	8	28 Aug, 2024
10 mg, 15 mg and 20 mg	17 Jun, 2022	1	17 Feb, 2034

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
11 mg	07 Nov, 2016	1		25 Mar, 2023	Extinguished
22 mg	28 Dec, 2020	1	19 Aug, 2021	14 Mar, 2034	Eligible